Research programme: non-opioid pain therapeutics- CerSci Therapeutics

Drug Profile

Research programme: non-opioid pain therapeutics- CerSci Therapeutics

Alternative Names: CT-044

Latest Information Update: 03 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator CERSCI Therapeutics
  • Class Non-opioid analgesics; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute pain
  • Research Neuropathic pain

Most Recent Events

  • 02 Aug 2017 CerSci Therapeutics receives a Direct-to-Phase II SBIR grant from National Institute on Drug Abuse for CT 044 development in Pain
  • 01 Aug 2017 CerSci Therapeutics plans clinical trial for CT 044 in late 2018
  • 08 Mar 2017 Early research in Neuropathic pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top